Proactive Investors - Run By Investors For Investors

Genprex retains pharma branding agency to select a name for its lead drug

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive Investors the biotech has moved one step closer to commercializing its flagship drug candidate Oncoprex by retaining pharmaceutical branding agency Addison Whitney.

Varner says Addison Whitney is helping with the naming process of the drug, which could take a few months to a year.

 
View full GNPX profile View Profile

Genprex, Inc. Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use